000 | 01594 a2200493 4500 | ||
---|---|---|---|
005 | 20250513231915.0 | ||
264 | 0 | _c20010222 | |
008 | 200102s 0 0 eng d | ||
022 | _a0250-7005 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aBroggini, M | |
245 | 0 | 0 |
_aCell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. _h[electronic resource] |
260 |
_bAnticancer research _c |
||
300 |
_a4835-40 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
650 | 0 | 4 |
_aCarboplatin _xtherapeutic use |
650 | 0 | 4 |
_aCarcinoma, Endometrioid _xdrug therapy |
650 | 0 | 4 | _aCell Cycle |
650 | 0 | 4 |
_aCell Cycle Proteins _xanalysis |
650 | 0 | 4 | _aChemotherapy, Adjuvant |
650 | 0 | 4 |
_aCisplatin _xtherapeutic use |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFollow-Up Studies |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMultivariate Analysis |
650 | 0 | 4 | _aNeoplasm Staging |
650 | 0 | 4 |
_aNeoplasm, Residual _xpathology |
650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aProportional Hazards Models |
650 | 0 | 4 | _aSurvival Rate |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 |
_acdc25 Phosphatases _xanalysis |
700 | 1 | _aBuraggi, G | |
700 | 1 | _aBrenna, A | |
700 | 1 | _aRiva, L | |
700 | 1 | _aCodegoni, A M | |
700 | 1 | _aTorri, V | |
700 | 1 | _aLissoni, A A | |
700 | 1 | _aMangioni, C | |
700 | 1 | _aD'Incalci, M | |
773 | 0 |
_tAnticancer research _gvol. 20 _gno. 6C _gp. 4835-40 |
|
999 |
_c11143276 _d11143276 |